The Vanishing Tumour: The Rise of Immunotherapy for Colorectal Cancer

For decades, the standard response to a bowel tumour was a cold blade and radical resection. Patients often traded their cancer for a life of permanent physical alterations and stoma bags. This aggressive approach was the only path to survival, yet it left deep scars on the human experience.

The Power of Immunotherapy for Colorectal Cancer

Recent clinical evidence shows that patients with mismatch repair-deficient (dMMR) tumours respond with startling intensity to immune checkpoint inhibitors. When administered before surgery, these drugs enable the body to identify and erase malignant cells with precision. The results are often near-universal major pathological responses, where the immune system clears the site before the surgeon even makes an incision.

Data suggests that for many MSI-H rectal cancer patients, the tumour disappears so completely that surgery becomes unnecessary. This shift toward 'organ preservation' allows patients to maintain their quality of life while remaining cancer-free under strict observation. It is a quiet victory for the patient’s anatomy, avoiding the trauma of the scalpel.

The Challenge of the Microsatellite-Stable Majority

Despite these successes, most patients possess microsatellite-stable (MSS) tumours that ignore current immune treatments. Researchers are currently testing:

• Combinations of radiation and chemotherapy to sensitise tumours.
• Novel immune modulators to bypass resistance.
• Circulating tumour DNA (ctDNA) to track molecular remnants.

While ctDNA cannot yet replace physical biopsies, it may soon help clinicians decide who can safely skip the operating theatre. Future progress depends on biomarker-driven trials that adapt to how an individual's body responds to therapy. The focus now shifts to expanding these benefits to the broader patient population.